['osteoarthritis of the knee']
['fx006 32 mg', 'tca ir 40']

        Inclusion Criteria:

          -  Written consent to participate in the study

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Symptoms associated with OA of the knee for ≥ 6 months prior to Screening (patient
             reported is acceptable)

          -  Currently meets American College of Rheumatology (ACR) Criteria (clinical and
             radiological) for OA

          -  Index knee pain for >15 days over the last month (as reported by the patient)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Ambulatory and in good general health

        Exclusion Criteria:

          -  Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, or arthritis associated with inflammatory bowel disease

          -  History of infection in the index knee joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee within 1 month of Screening

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint within 12 months of Screening

          -  IA corticosteroid (investigational or marketed) in any joint within 6 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Intravenous or Intramuscular corticosteroids (investigational or marketed) within 3
             months of Screening

          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening

          -  Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2
             weeks of Screening

          -  Any other IA investigational drug/biologic use within 6 months of Screening or 5
             half-lives (whichever is longer)

          -  Prior use of FX006

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
      